PDCD1 and hepatocellular carcinoma: In 2020, the IMbrave150 study in patients with unresectable HCC and no prior systemic drug therapy showed a statistically significant difference in OS between sorafenib treatment and atezo + bev treatment, a combination therapy consisting of an anti-PD1 inhibitor and an anti-VEGF inhibitor [14].